Low Levels of Urinary PSA Better Identify Prostate Cancer Patients.
biomarkers
diagnosis
early detection
prostate cancer detection
prostate cancer prevention
screening
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Jul 2021
16 Jul 2021
Historique:
received:
27
05
2021
revised:
09
07
2021
accepted:
13
07
2021
entrez:
24
7
2021
pubmed:
25
7
2021
medline:
25
7
2021
Statut:
epublish
Résumé
Serum prostatic specific antigen (PSA) has proven to have limited accuracy in early diagnosis and in making clinical decisions about different therapies for prostate cancer (PCa). This is partially due to the fact that an increase in PSA in the blood is due to the compromised architecture of the prostate, which is only observed in advanced cancer. On the contrary, PSA observed in the urine (uPSA) reflects the quantity produced by the prostate, and therefore can give more information about the presence of disease. We enrolled 574 men scheduled for prostate biopsy at the urology clinic, and levels of uPSA were evaluated. uPSA levels resulted lower among subjects with PCa when compared to patients with negative biopsies. An indirect correlation was observed between uPSA amount and the stage of disease. Loss of expression of PSA appears as a characteristic of prostate cancer development and its evaluation in urine represents an interesting approach for the early detection of the disease and the stratification of patients.
Identifiants
pubmed: 34298784
pii: cancers13143570
doi: 10.3390/cancers13143570
pmc: PMC8303247
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fondazione Umberto Veronesi
ID : Postdoctoral Fellowship
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG no. 15257
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 5×1000 no. 12182
Références
N Engl J Med. 2009 Mar 26;360(13):1310-9
pubmed: 19297565
J Natl Cancer Inst. 2010 May 5;102(9):605-13
pubmed: 20413742
J Urol. 2011 May;185(5):1650-5
pubmed: 21419439
Eur Urol. 2015 Sep;68(3):464-70
pubmed: 25454615
J Urol. 2016 May;195(5):1390-1396
pubmed: 26678954
Int Braz J Urol. 2009 May-Jun;35(3):299-308; discussion 308-9
pubmed: 19538765
Clin Chem. 2006 Apr;52(4):562-73
pubmed: 16484332
APMIS. 2016 Jun;124(6):433-5
pubmed: 27150257
Eur Urol. 1996;29(4):407-12
pubmed: 8791046
BJU Int. 2015 Dec;116(6):873-9
pubmed: 25523210
Eur Urol. 2016 Nov;70(5):740-748
pubmed: 27108162
Can Urol Assoc J. 2007 Nov;1(4):377-81
pubmed: 18542821
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Mod Pathol. 2019 Sep;32(9):1310-1319
pubmed: 30980038
JAMA. 2015 Nov 17;314(19):2054-61
pubmed: 26575061
J Urol. 2013 Mar;189(3):1110-6
pubmed: 22999998
Epidemiol Perspect Innov. 2006 Oct 05;3:11
pubmed: 17022816
Urology. 2009 Nov;74(5):1169-73
pubmed: 19476978
Prostate Cancer Prostatic Dis. 2020 Dec;23(4):607-614
pubmed: 32382078
Eur Urol. 2013 Nov;64(5):703-9
pubmed: 23721957
Prostate. 2013 Feb 15;73(3):242-9
pubmed: 22821767
N Engl J Med. 2009 Mar 26;360(13):1320-8
pubmed: 19297566
Lancet. 2017 Feb 25;389(10071):815-822
pubmed: 28110982
J Cancer Res Clin Oncol. 2003 Nov;129(11):662-8
pubmed: 14513368
Oncotarget. 2019 Sep 10;10(52):5439-5453
pubmed: 31534629
Cancer. 2010 May 1;116(9):2140-7
pubmed: 20309846
JAMA. 2015 Nov 17;314(19):2077-9
pubmed: 26575066
J Urol. 2000 Jun;163(6):1739-42
pubmed: 10799172
Urol Oncol. 2020 Mar 30;:
pubmed: 32241692
Ann Intern Med. 2012 Jul 17;157(2):120-34
pubmed: 22801674
JAMA. 2018 May 8;319(18):1914-1931
pubmed: 29801018
Sci Rep. 2016 May 10;6:25776
pubmed: 27161545
Eur Urol. 2019 Jul;76(1):43-51
pubmed: 30824296